Tag: DCT
Decentralized clinical trials (DCTs) are transforming the way we approach clinical research by enabling more flexible and patient-centric methodologies. As companies embrace these trials for everything from supplements to skincare products, ensuring compliance in DCTs becomes essential. This blog will explore the critical elements of compliance in decentralized clinical trials and offer strategies to navigate these evolving landscapes successfully. What Are Decentralized Clin
By Ben Brockman
When it comes to clinical trials, a pilot study is an invaluable tool for ensuring success. Acting as a trial run for the full-scale study, a pilot study allows researchers to refine methodologies, identify potential issues, and determine the feasibility of their research design. In industries like skincare, supplements, cosmetics, and pet health, conducting a pilot study can significantly improve the quality and credibility of claims, saving both time and resources in the l
By Ben Brockman
Decentralized clinical trials (DCTs) have revolutionized the way clinical research is conducted. By utilizing technology to reach participants remotely, these trials have opened doors to faster enrollment, greater diversity, and enhanced convenience for both researchers and participants. However, as with any technology-driven process, data security in decentralized clinical trials has become a critical concern. Protecting sensitive health information (PHI) while ensuring com
By Ben Brockman
With new products hitting the market everyday, consumers are more informed than ever and demand proof behind product claims. Whether it’s a new supplement, a skincare product, or even a pet health innovation, brands need evidence that their offerings work as advertised. This is where parallel studies shine. Known for their straightforward design and robust data, parallel studies are a powerful tool for brands to establish transparency and build trust with their audience. In
By Ben Brockman
In the fast-evolving world of product development, in silico testing is emerging as a powerful and innovative tool. By leveraging advanced computer simulations and modeling, this method is transforming how brands in industries like cosmetics, skincare, supplements, superfoods, and pet health validate their products. Here’s a high-level overview of what in silico testing is, its benefits, applications, and why it’s gaining momentum in clinical trials. What is In Silico Testing
By Ben Brockman
Participant dropouts are one of the most common and costly challenges in clinical trials. When participants leave a study early, timelines slip, data quality suffers, and results can become harder to interpret. Dropouts in clinical trials happen when participants discontinue a study before completion, often due to burden, confusion, lack of engagement, or unmet expectations. You can reduce dropouts by designing participant-friendly protocols, setting clear expectations, maint
By Ben Brockman
Clinical trials are no longer just for pharmaceuticals. Today, health, wellness, and CPG brands rely on clinical research to validate product performance, support marketing claims, and build consumer trust. As research methods evolve, brands are increasingly choosing between centralized clinical trials, decentralized clinical trials, or a mix of both. Understanding the difference matters because the trial model you choose affects cost, timelines, participant diversity, and th
By Ben Brockman
Decentralized clinical trials are redefining how research is conducted, bringing participation directly to people’s homes, and breaking down the traditional barriers of location, time, and access. At the heart of this transformation is telehealth: a powerful enabler of remote communication, monitoring, and data collection. In this article, we explore how telehealth is reshaping clinical trials, highlight its benefits and challenges, and examine what the future holds for this
By Ben Brockman
Clinical trials in 2025 look dramatically different from just a few years ago, but many of the underlying challenges are still present....
By Ben Brockman